Influence of Existing Primary Cancers on Survival Outcomes in Melanoma Patients
By
Alessandra Buja
Stefano Guzzinati
Chiara Trevisiol
Claudio Palmeri
Marcello Di Pumpo
Paolo Del Fiore
Carlo Riccardo Rossi
Carmen Stocco
Pierfranco Conte
Manuel Zorzi
Simone Mocellin
September 14, 2026
Clinical Scorecard: Influence of Existing Primary Cancers on Survival Outcomes in Melanoma Patients
At a Glance
Category Detail
Condition Cutaneous Malignant Melanoma Key Mechanisms Prevalent primary cancers may complicate melanoma's clinical course and affect overall survival. Target Population Patients diagnosed with cutaneous melanoma and prevalent primary cancers. Care Setting Population-based cancer registry analysis.
Key Highlights
4.5% of melanoma patients had prevalent tumors. Prostate, breast, colon, and kidney cancers were the most common additional cancers. Prevalent tumors were associated with increased all-cause mortality risk. Healthcare costs were higher for patients with prevalent tumors. Multimorbidity considerations are important in melanoma management. Guideline-Based Recommendations
Diagnosis
Assess for prevalent primary cancers at the time of melanoma diagnosis. Management
Incorporate multimorbidity considerations into the management of melanoma patients. Monitoring & Follow-up
Monitor overall health and comorbid conditions in melanoma patients. Risks
Prevalent tumors increase the risk of all-cause mortality in melanoma patients. Patient & Prescribing Data
Melanoma patients with a history of prevalent primary cancers.
Management strategies should consider the impact of existing malignancies on treatment options.
Clinical Best Practices
Utilize population-based data to inform clinical decision-making. Evaluate the impact of comorbidities on melanoma prognosis. Related Resources & Content
